• 中国科技核心期刊
  • 中文科技期刊数据库刊源
  • 中国科技论文统计源期刊
  • 美国化学文摘社《化学文摘》刊源
Volume 34 Issue 3
May  2022
Turn off MathJax
Article Contents
Xiao-meng JIA, Ying-long HOU. Recent advances in treatment of coronary in-stent restenosis[J]. Chinese Heart Journal, 2022, 34(3): 344-347, 351. doi: 10.12125/j.chj.202103023
Citation: Xiao-meng JIA, Ying-long HOU. Recent advances in treatment of coronary in-stent restenosis[J]. Chinese Heart Journal, 2022, 34(3): 344-347, 351. doi: 10.12125/j.chj.202103023

Recent advances in treatment of coronary in-stent restenosis

doi: 10.12125/j.chj.202103023
  • Received Date: 2021-03-08
  • Accepted Date: 2021-12-27
  • Rev Recd Date: 2021-12-08
  • Publish Date: 2022-05-26
  • Percutaneous coronary intervention (PCI) has become an effective means for the treatment of coronary stenosis. Even with the wild use of drug-eluting stent and drug-coated balloons, restenosis after PCI is an important factor affecting its long-term efficacy and prognosis. In-stent restenosis (ISR) remains a major group of restenosis after PCI, which can lead to the recurrence of major adverse cardiovascular events, including angina, acute myocardial infarction, and even sudden cardiac death. Therefore, focusing again on the therapy of ISR is still of important clinical significance.

     

  • loading
  • [1]
    Lansky A, Grubman D, Scheller B. Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis[J]. Eur Heart J, 2020, 41(38): 3729 – 3731. doi: 10.1093/eurheartj/ehz731
    [2]
    Giacoppo D, Alfonso F, Xu B, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis[J]. J Am Coll Cardiol, 2020, 75(21): 2664 – 2678. doi: 10.1016/j.jacc.2020.04.006
    [3]
    Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era[J]. J Am Coll Cardiol, 2010, 56(23): 1897 – 1907. doi: 10.1016/j.jacc.2010.07.028
    [4]
    Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome[J]. Circulation, 1999, 100(18): 1872 – 1878. doi: 10.1161/01.CIR.100.18.1872
    [5]
    Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J]. Circ Cardiovasc Interv, 2019, 12(8): e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023
    [6]
    Nicol P, Bulin A, Castellanos MI, et al. Preclinical investigation of neoatherosclerosis in magnesium-based bioresorbable scaffolds versus thick-strut drug-eluting stents[J]. EuroIntervention, 2020, 16(11): e922 – e929. doi: 10.4244/EIJ-D-19-00747
    [7]
    Nakamura D, Yasumura K, Nakamura H, et al. Different neoatherosclerosis patterns in drug-eluting- and bare-metal stent restenosis - optical coherence tomography study[J]. Circ J, 2019, 83(2): 313 – 319. doi: 10.1253/circj.CJ-18-0701
    [8]
    Mazin I, Paul G, Asher E. Neoatherosclerosis - from basic concept to clinical implication[J]. Thromb Res, 2019, 178: 12 – 16. doi: 10.1016/j.thromres.2019.03.016
    [9]
    Borovac JA, D'Amario D, Vergallo R, et al. Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge[J]. Eur Heart J Cardiovasc Pharmacother, 2019, 5(2): 105 – 116. doi: 10.1093/ehjcvp/pvy036
    [10]
    Otsuka F, Byrne RA, Yahagi K et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment[J]. Eur Heart J, 2015, 36(32): 2147 – 2159. doi: 10.1093/eurheartj/ehv205
    [11]
    Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2): 87 – 165. doi: 10.1093/eurheartj/ehy394
    [12]
    Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)[J]. Eur Heart J, 2020, 41(38): 3715 – 3728. doi: 10.1093/eurheartj/ehz594
    [13]
    Kufner S, Joner M, Thannheimer A, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease[J]. Circulation, 2019, 139(3): 325 – 333. doi: 10.1161/CIRCULATIONAHA.118.038065
    [14]
    Natsuaki M, Kozuma K, Morimoto T, et al. Final 3-year outcome of a randomized trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent trial[J]. Circ Cardiovasc Interv, 2015, 8(10): e002817. doi: 10.1161/CIRCINTERVENTIONS.115.002817
    [15]
    Natsuaki M, Kozuma K, Morimoto T, et al. Five-year outcome of a randomised trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: the NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent trial (NEXT)[J]. EuroIntervention, 2018, 14(7): 815 – 818. doi: 10.4244/EIJ-D-17-01050
    [16]
    Alfonso F, Pérez-Vizcayno MJ, Hernández R, et al. Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis[J]. Am J Cardiol, 1999, 83(8): 1268 – 1270. doi: 10.1016/S0002-9149(99)00071-5
    [17]
    Mitomo S, Naganuma T, Takagi K, et al. Comparison between plain old balloon angioplasty and drug-eluting stent implantation for the treatment of stent fracture[J]. J Interv Cardiol, 2015, 28(4): 365 – 373. doi: 10.1111/joic.12215
    [18]
    Baan J Jr, Claessen BE, Dijk KB, et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the dare trial[J]. JACC Cardiovasc Interv, 2018, 11(3): 275 – 283. doi: 10.1016/j.jcin.2017.10.024
    [19]
    Verdoia M, Negro F, Kedhi E, et al. Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials[J]. Vascul Pharmacol, 2021, 138: 106859. doi: 10.1016/j.vph.2021.106859
    [20]
    Hong MK, Lee SY. Differential effects of drug-coated balloon angioplasty for in-stent restenosis[J]. J Am Coll Cardiol, 2020, 75(21): 2679 – 2681. doi: 10.1016/j.jacc.2020.04.005
    [21]
    Widder JD, Cortese B, Levesque S, et al. Coronary artery treatment with a urea-based paclitaxel-coated balloon: the European-wide FALCON all-comers DCB registry (FALCON Registry)[J]. EuroIntervention, 2019, 15(4): e382 – e388. doi: 10.4244/EIJ-D-18-00261
    [22]
    Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study[J]. EuroIntervention, 2015, 11(8): 926 – 934. doi: 10.4244/EIJY14M08_12
    [23]
    Xi Y, Chen J, Bi Y, et al. Long-term clinical safety and efficacy of drug-coated balloon in the treatment of in-stent restenosis: a meta-analysis and systematic review[J]. Catheter Cardiovasc Interv, 2020, 96(2): E129 – E141. doi: 10.1002/ccd.28572
    [24]
    Bausback Y, Wittig T, Schmidt A, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease[J]. J Am Coll Cardiol, 2019, 73(6): 667 – 679. doi: 10.1016/j.jacc.2018.11.039
    [25]
    Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials[J]. J Am Heart Assoc, 2018, 7(24): e011245. doi: 10.1161/JAHA.118.011245
    [26]
    Heilmann T, Richter C, Noack H, et al. Drug release profiles of different drug-coated balloon platforms[J]. Eur Cardiol Rev, 2010, 6(4): 40 – 44. doi: 10.15420/ECR.2010.8.2.40
    [27]
    Scheller B, Vukadinovic D, Jeger R, et al. Survival after coronary revascularization with paclitaxel-coated balloons[J]. J Am Coll Cardiol, 2020, 75(9): 1017 – 1028. doi: 10.1016/j.jacc.2019.11.065
    [28]
    Ishihara T, Iida O, Takahara M, et al. Improved crossability with novel cutting balloon versus scoring balloon in the treatment of calcified lesion[J]. Cardiovasc Interv Ther, 2021, 36(2): 198 – 207. doi: 10.1007/s12928-020-00663-5
    [29]
    Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT)[J]. J Am Coll Cardiol, 2004, 43(6): 943 – 949. doi: 10.1016/j.jacc.2003.09.054
    [30]
    Kong J, Hou J, Ma L, et al. Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis[J]. Arch Cardiovasc Dis, 2013, 106(2): 79 – 85. doi: 10.1016/j.acvd.2012.10.004
    [31]
    Traxler D, Hemetsberger R, Spannbauer A, et al. Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries[J]. Histol Histopathol, 2020, 35(7): 653 – 663. doi: 10.14670/HH-18-177
    [32]
    Kufner S, Joner M, Schneider S, et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial[J]. JACC Cardiovasc Interv, 2017, 10(13): 1332 – 1340. doi: 10.1016/j.jcin.2017.04.024
    [33]
    Alfonso F, Cuesta J, García Del Blanco B, et al. Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study[J]. Coron Artery Dis, 2021, 32(2): 96 – 104. doi: 10.1097/MCA.0000000000000904
    [34]
    Lee T, Shlofmitz RA, Song L, et al. The effectiveness of excimer laser angioplasty to treat coronary in-stent restenosis with peri-stent calcium as assessed by optical coherence tomography[J]. EuroIntervention, 2019, 15(3): e279 – e288. doi: 10.4244/EIJ-D-18-00139
    [35]
    Nishino M, Lee Y, Nakamura D, et al. Differences in optical coherence tomographic findings and clinical outcomes between excimer laser and cutting balloon angioplasty for focal in-stent restenosis lesions[J]. J Invasive Cardiol, 2012, 24(10): 478 – 483.
    [36]
    Miyazaki T, Ashikaga T, Fukushima T, et al. Treatment of in-stent restenosis by excimer laser coronary atherectomy and drug-coated balloon: serial assessment with optical coherence tomography[J]. J Interv Cardiol, 2019, 2019: 6515129. doi: 10.1155/2019/6515129
    [37]
    Megaly M, Glogoza M, Xenogiannis I, et al. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis[J]. Catheter Cardiovasc Interv, 2021, 97(1): 32 – 38. doi: 10.1002/ccd.28716
    [38]
    Correa-Sadouet C, Rodríguez-Granillo AM, Gallardo C, et al. Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention[J]. Future Cardiol, 2021, 17(4): 539 – 547. doi: 10.2217/fca-2020-0161
    [39]
    Alfonso F, Bastante T, Antuña P, et al. Coronary Lithoplasty for the Treatment of Undilatable Calcified De Novo and In-Stent Restenosis Lesions[J]. JACC Cardiovasc Interv, 2019, 12(5): 497 – 499. doi: 10.1016/j.jcin.2018.12.025
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Article views (91) PDF downloads(24) Cited by()
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return